The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2024 | Key biomarkers for advanced gastric cancer therapy decision-making
Nicola Fazio, MD, PhD, Istituto Europeo di Oncologia, Milan, Italy, discusses key biomarkers essential for therapeutic decision-making in advanced gastric or gastroesophageal junction adenocarcinoma. HER2 and PD-L1 are primary markers influencing treatment pathways, where HER2-positive cases may benefit from chemotherapy with trastuzumab and pembrolizumab, as shown in the KEYNOTE-811 study (NCT03615326). Emerging biomarkers like claudin 18.2 and MMR/MSI are also highlighted for their prognostic value, with promising data from the SPOTLIGHT (NCT04186845) and GLOW (NCT03653507) trials supporting zolbetuximab for claudin 18.2-positive cases. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
